BioVenture VoiCes with Chris Garabedian Episode 8: Canaan Partners' Julie Grant
23 snips
Dec 18, 2024 Julie Grant, a general partner at Canaan Partners with a robust background in healthcare investments from Goldman Sachs and Genentech, shares her dynamic career journey. She highlights the importance of industry connections and reflects on her time at Genentech, emphasizing the complexities of biotech commercialization. Julie discusses Canaan's bold investment strategies in new medicine categories and the significance of innovation in drug development, advocating for contrarian thinking to drive effective therapies forward. Her insights offer a fascinating look into the evolving landscape of healthcare investments.
AI Snips
Chapters
Transcript
Episode notes
Learning from Success and Failure
- Julie Grant's Genentech experience included working on successful and unsuccessful drugs, including GA-101 (Obinutuzumab) and early ADCs.
- This provided valuable lessons in drug development and navigating its uncertainties.
Find Your Passion, Embrace Teamwork
- Find something you love in drug development; careers are long.
- Embrace teamwork, especially with diverse experts who can strengthen decision-making.
Genentech's Evolving Culture
- Genentech's culture varied across departments and times.
- Open communication between leadership and lower levels, even if disruptive, facilitated informed decisions.